Index Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, 947 948 Anorectal melanoma RT for, 1035 B Bacille Calmette-Guerin (BCG) in melanoma, 1008 BCG. See Bacille Calmette-Guerin (BCG) BRAF-mutant melanoma algorithm for, 1052 1053 C Chemotherapy for HNM, 1100 Chest x-ray in workup and staging of malignant melanoma, 967 Children cutaneous melanoma arising in, 1064 1065 Cutaneous melanoma arising in childhood, 1064 1065 high-risk RT for, 1032 1033 surviving, 989 1002. See also Melanoma D Dermis unknown primary melanoma in, 1062 1063 Desmoplastic melanoma RT for, 1033 E Elective lymphadenectomy in regional lymph node management, 977 978 Eye(s) melanoma arising on, 1067 1069 Surg Clin N Am 94 (2014) 1127 1134 http://dx.doi.org/10.1016/s0039-6109(14)00131-5 surgical.theclinics.com 0039-6109/14/$ see front matter ª 2014 Elsevier Inc. All rights reserved.
1128 Index F FDG-PET/CT. See 18-fluoro-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) 18-Fluoro-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in workup and staging of malignant melanoma, 968 G Gender as factor in melanoma, 947 H Head and neck melanoma (HNM), 1091 1113 classification and staging of, 1093 clinical presentation of, 1092 1093 epidemiology of, 1091 1092 history of, 1092 introduction, 1091 1092 laboratory investigations of, 1093 1094 mucosal RT for, 1034 1035 physical examination of, 1092 1093 treatment and pathologic staging of, 1094 1100 adjuvant therapy, 1100 neck dissection, 1097 1100 parotid management, 1097 primary lesion related, 1094 1095 reconstruction, 1100 1108 cheek, 1104 1105 ears, 1106 1108 eyelids, 1104 forehead, 1103 1104 lips, 1105 1106 Mohs surgery, 1108 nose, 1106 scalp, 1102 1103 techniques, 1101 1102 timing of, 1100 SLNB and lymphatic drainage patterns, 1095 1097 HNM. See Head and neck melanoma (HNM) Hyperthermic isolated limb perfusion in melanoma, 1004 1006 I IL-2. See Interleukin-2 (IL-2) ILI. See Isolated limb infusion (ILI) Immune adjuvants in melanoma, 1024 1025 Immunomodulators in melanoma, 1024 1025
Index 1129 Immunosuppression melanoma related to, 952 Immunotherapy in melanoma, 1050 1051 Interferon adjuvant therapy with results of, 1054 1055 Interleukin-2 (IL-2) in melanoma, 1008 1009 Intra-arterial regional perfusion therapies in melanoma, 1004 1008 hyperthermic isolated limb perfusion, 1004 1006 ILI, 1006 1008 Intralesional and topical therapies in melanoma, 1008 1010 BCG, 1008 IL-2, 1008 1009 PV-10/rose bengal, 1009 T-VEC, 1009 1010 Intralesional immunotherapy in melanoma, 1026 Isolated limb infusion (ILI) in melanoma, 1006 1008 L Lentigo maligna (LM) RT for, 1032 LM. See Lentigo maligna (LM) LND. See Lymph node dissection (LND) Locoregional therapies in melanoma, 1003 1015. See also specific types, e.g. Intra-arterial regional perfusion therapies intra-arterial regional perfusion therapies, 1004 1008 intralesional and topical therapies, 1008 1010 RT, 1010 1012 surgical resection, 1003 1004 systemic therapy, 1010 topical agents, 1010 Lymph node dissection (LND) in regional lymph node management, 983 985 Lymphadenectomy elective in regional lymph node management, 977 978 Lymphoscintigraphy in regional lymph node management, 981 M Malignant melanoma risk factors for, 963 964 surgical treatment of
1130 Index Malignant (continued) introduction, 973 primary cutaneous melanoma, 974 976 principles of, 973 988 regional lymph nodes, 976 985 workup and staging of, 963 972 biopsy in principles of, 964 965 imaging in, 967 968 laboratory tests in, 969 pathologic analysis in, 965 966 SLNB in, 966 967 Melanoma(s), 945 962. See also specific types, e.g., Neurotropic melanoma age as factor in, 947 948 arising in eye, 1067 1069 arising on mucosal surfaces, 1065 1067 BRAF-mutant algorithm for, 1052 1053 demographics and trends, 946 948 early detection of, 954 956 economic impact of, 946 epidemiology of, 946 948 gender predilection for, 947 global incidence of, 946 head and neck, 1091 1113. See also Head and neck melanoma (HNM) high-risk adjuvant therapy for, 1053 1056 defined, 1053 1054 impact of, 946 948 incidence of, 989 introduction, 945 946, 989 990 locoregional therapies in, 1003 1015. See also Locoregional therapies, in melanoma malignant, 963 972. See also Malignant melanoma in non-caucasian populations, 1115 1126 anatomy related to, 1116 causes of, 1120 1122 clinical presentation of, 1116 1117 epidemiology of, 1116 histologic type, 1117 1119 interventions for, 1123 introduction, 1115 1116 outcomes of, 1122 1123 stage at diagnosis, 1119 1120 in older persons, 948 prevalence of, 963 prevention of, 953 primary cutaneous management of, 974 976 race as factor in, 946 947 recurrence of diagnosis and management, 997 999
Index 1131 local, satellite, and in-transit recurrence, 998 local scar recurrence, 997 metastatic recurrence, 998 999 regional recurrence, 998 risk factors for, 948 953, 963 964 exposures, 951 953 host factors, 948 951 RT in, 1031 1047. See also Radiation therapy (RT), in melanoma stage IV algorithm for, 1051 1053 introduction, 1075 1076 surgical treatment of, 1075 1089 as adjuvant therapy, 1082 1083 M1a disease, 1078 1079 M1b disease, 1079 M1c disease, 1079 1082 preoperative planning for, 1076 1082 surviving, 989 1002 introduction, 989 990 prognostic factors in, 990 992 surveillance in, 992 997 NCCN Guidelines, 993 996 patient education and risk factor modification, 996 psychosocial distress evaluation and coping mechanisms, 997 tailoring schedules to individual patient needs, 996 variations in follow-up practices, 993 systemic therapy in, 1049 1058. See also Systemic therapy, in melanoma unusual presentations of, 1059 1073 cutaneous melanoma arising in childhood, 1064 1065 introduction, 1060 melanoma arising in eye, 1067 1069 arising on mucosal surfaces, 1065 1067 unknown primary melanoma in dermis and subcutaneous tissue, 1062 1063 in regional nodes, 1060 1062 in visceral organs, 1063 1064 vaccines for, 1017 1030. See also Vaccine(s), melanoma wild-type algorithm for, 1052 1053 Mohs surgery in HNM management, 1108 Molecularly targeted therapies in melanoma, 1050 1051 Mucosal surfaces melanoma arising on, 1065 1067 N Neurotropic melanoma RT for, 1033
1132 Index Non-Caucasian populations melanoma in, 1115 1126. See also Melanoma, in non-caucasian populations O Older persons melanoma in, 948 P Primary cutaneous melanoma management of, 974 976 background of, 974 intermediate-thickness melanoma, 975 melanoma in situ, 976 thick melanoma, 976 thin melanoma, 974 975 PV-10/rose bengal in melanoma, 1009 R Race as factor in melanoma, 946 947 Radiation therapy (RT) for HNM, 1100 in melanoma, 1010 1012, 1031 1047 introduction, 1031 for local control, 1032 1035 anorectal melanoma, 1035 desmoplastic and neurotropic melanoma, 1033 head and neck mucosal melanoma, 1034 1035 high-risk cutaneous melanoma, 1032 1033 LM, 1032 for nodal basin control, 1035 1043 adjuvant radiation, 1036 1041 morbidity data, 1041 1043 risk factors for nodal basin recurrence, 1035 1036 Regional lymph nodes management of, 976 985 background, 976 elective lymphadenectomy in, 977 978 indications for, 980 981 LND in, 983 985 SLEB in, 978 979 technical points, 981 983 unknown primary melanoma in, 1060 1062. See also Unknown primary melanoma, in regional nodes RT. See Radiation therapy (RT) S Sentinel lymph node biopsy (SLNB) for HNM, 1095 1097
Index 1133 in regional lymph nodes management, 978 979, 981 983 clinical evidence for, 979 980 in workup and staging of malignant melanoma, 966 967 SLNB. See Sentinel lymph node biopsy (SLNB) Socioeconomic status melanoma related to, 952 953 Subcutaneous tissue unknown primary melanoma in, 1062 1063 Systemic therapy in melanoma, 1010, 1049 1058 adjuvant therapy, 1053 1056 clinical trials, 1055 1056 interferon results, 1054 1055 algorithm for stage IV melanoma, 1051 1053 immunotherapy, 1050 1051 introduction, 1049 1050 molecularly targeted therapies, 1050 1051 relevant biology related to, 1050 1051 T T-VEC. See Talimogene laherparepvec (T-VEC) Talimogene laherparepvec (T-VEC) in melanoma, 1009 1010 Topical agents in melanoma, 1010 U Ultrasound in workup and staging of malignant melanoma, 967 968 Ultraviolet (UV) light melanoma related to, 951 952 Unknown primary melanoma in dermis and subcutaneous tissue, 1062 1063 in regional nodes, 1060 1062 initial evaluation of, 1060 1061 management of adjuvant therapy in, 1061 1062 surgical, 1061 relevant biology of, 1061 in visceral organs, 1063 1064 Unusual presentations of melanoma, 1059 1073. See also specific types and Melanoma, unusual presentations of V Vaccine(s) melanoma, 1017 1030 allogeneic, 1021 1023
1134 Index Vaccine(s) (continued) autologous, 1018 1021 future directions in, 1026 1027 ganglioside, 1023 immune adjuvants and immunomodulators, 1024 1025 intralesional immunotherapy, 1026 introduction, 1017 1018 peptide, 1023 1024 Visceral organs unknown primary melanoma in, 1063 1064